Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in Türkiye
Genes · 03.12.2025 · 16 (12) · 1446
DOI: 10.3390/genes16121446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 03.12.2025. Verfasst von Kübra Canaslan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dokuz Eylul University, Izmir 35330, Türkiye. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Genomic profiling guides treatment in metastatic non-small-cell lung cancer (mNSCLC), yet country-level data from Türkiye remain limited.
Methods
We retrospectively analyzed consecutive patients with mNSCLC diagnosed between January 2018 and March 2025 across tertiary centers in all seven regions. Variables included demographics, smoking, histology, testing modality (single-gene vs. next-generation sequencing [NGS]), targetable genomic alterations (TGAs) and co-mutations, and programmed death-ligand 1 (PD-L1) tumor proportion score.
Results
Among 1023 patients (mean age 64 years; 76.4% male), tobacco exposure was frequent (mean 42.1 pack-years); 16.9% were never-smokers. NGS use increased over time, exceeding 90% by 2025. TGAs were detected in 28.3% (EGFR 16.0%, ALK 5.0%, KRAS G12C 2.6%, BRAF V600E 3.2%; ROS1, MET exon 14, HER2, NTRK ≤ 2.5%; no RET). EGFR alterations occurred in 19% of non-squamous carcinomas and 6% of squamous cell carcinomas (SCCs), suggesting an intermediate East–West pattern. Among NGS-tested samples, TP53 was the most frequent co-mutation (33.1%), followed by alterations in CDKN2A, PIK3CA, FGFR, STK11, and KEAP1.
Conclusions
In this large, multicenter Turkish real-world cohort, the TGA spectrum broadly mirrors global patterns while revealing local nuances; EGFR mutations were more frequent than expected in SCC, and nationwide NGS adoption is accelerating. Limitations include retrospective design, non-centralized PD-L1 testing, and missing data. Prospective, standardized studies integrating outcomes and resistance mechanisms are warranted to refine regional precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dokuz Eylul University, Izmir 35330, Türkiye.
- Department of Medical Oncology, Atatürk University, Erzurum 25240, Türkiye.
- Department of Medical Oncology, Antalya Research and Training Hospital, Antalya 07100, Türkiye.
- Department of Medical Oncology, Bilkent City Hospital, Ankara 06800, Türkiye.
- Department of Medical Oncology, Karadeniz Technical University, Trabzon 61080, Türkiye.
- Department of Medical Oncology, Dicle University, Diyarbakır 21280, Türkiye.
ORCID-Profile: Kübra Canaslan, Fahriye Merve Balcıoğlu, Banu Öztürk, Öznur Bal, Görkem Turhan, Hayati Arvas
Zitieren
APA
Canaslan, K., Eken, E., Bilici, M., Balcıoğlu, F. M., Öztürk, B., Çakmak, M., Bal, Ö., Turhan, G., Özdemir, F., Arvas, H., Urakçı, Z., Çiçek, E., Turna, Z. H., & Karaoğlu, A. (2025). Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in Türkiye. Genes, 16(12), 1446. https://doi.org/10.3390/genes16121446
Vancouver
Canaslan K, Eken E, Bilici M, Balcıoğlu FM, Öztürk B, Çakmak M, et al. Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in Türkiye. Genes. 2025;16(12):1446. doi:10.3390/genes16121446
BibTeX
@article{Canaslan2025,
author = {Canaslan, Kübra and Eken, Emre and Bilici, Mehmet and Balcıoğlu, Fahriye Merve and Öztürk, Banu and Çakmak, Mehmet and Bal, Öznur and Turhan, Görkem and Özdemir, Feyyaz and Arvas, Hayati and Urakçı, Zuhat and Çiçek, Ebru and Turna, Zeynep Hande and Karaoğlu, Aziz},
title = {Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in Türkiye},
journal = {Genes},
year = {2025},
volume = {16},
number = {12},
pages = {1446},
doi = {10.3390/genes16121446}
}
EUVIMED